Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.

Drug Category: Array
Conference Category: Array
Lead Author: Lunning M, O'Brien S, et al.
Published Date: 02/06/2015
Download Link: /ASCO%20Doublet%20Poster%20FINAL.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top